Altamira Therapeutics Ltd. Gain Loss On Changes In Effect Of Limiting Reimbursement Rights To Asset Ceiling
Altamira Therapeutics Ltd. (CYTOF) reported Gain Loss On Changes In Effect Of Limiting Reimbursement Rights To Asset Ceiling of CHF 63.21 thousand for the 6-month period ending 2021-06-30, per its 6-K filed 2021-09-08.
Discontinued › Income Statement › Other Income
ifrs-full:GainLossOnChangesInEffectOfLimitingReimbursementRightsToAssetCeiling · last filed 2021-09-08
- 2021-06-30: Gain Loss On Changes In Effect Of Limiting Reimbursement Rights To Asset Ceiling 6 month 63.21K CHF.
| Period end | Gain Loss On Changes In Effect Of Limiting Reimbursement Rights To Asset Ceiling 6 month |
|---|---|
| 2021-06-30 | 63.21K CHF 6-K · filed 2021-09-08 |